DHPC Systemic and inhaled quinolone and fluoroquinolone antibiotics – risk of disabling, long-lasting and potentially irreversible side effects.
Following a European safety review, Mercury Pharmaceuticals Limited in agreement with the MHRA and the European Medicines Agency (EMA) would like to inform you of the safety information regarding risk of disabling, long-lasting and potentially irreversible side effects.